Theodoros Tzamalis

Internist, Hematologist/Oncologist enjoying drinking coffee, reading (medical) literature and listening to jazz music.

[Benlazar S M A @smbenlazar]

Newly diagnosed acute myeloid leukemia in Fit patients: 2026 treatment algorithms https://t.co/wq2Cbwlk9Q #leusm @n_gangat

[Benlazar S M A @smbenlazar]

First line treatment of mantle cell lymphoma : EHA guide lines #lymsm

[Vincent Rajkumar @VincentRK]

Just out!! In @NEJM - Our randomized trial in myeloma (ENDURANCE trial) shows limited duration of lenalidomide maintenance is just as good as indefinite therapy, with less side effects!!! @eaonc @theNCI

Implications are HUGE. This is a drug we spends billions on each year:

-Less side effects
-Less second cancers
-Similar overall survival
-Less cost
@myelomaMD @Myeloma_Doc @SagarLonialMD

National NCI funded trial led by @eaonc and joined by @ALLIANCE_org & @SWOG

https://t.co/k8nGWeSA03

[JAMA Oncology @JAMAOnc]

Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to more severe toxic effects, mainly infections, without survival benefit compared to atezolizumab alone. https://t.co/NQnMVhHGmk

[MV Chandrakanth @ChandrakanthMv]

Dato-DXd Improves Survival in First-Line Advanced TNBC

TROPION-Breast02 | Phase III Trial | Annals of Oncology 2026

• In patients with previously untreated, locally recurrent inoperable or metastatic TNBC who were not eligible for immunotherapy, Dato-DXd significantly outperformed investigator's choice chemotherapy.

• Median PFS: 10.8 vs 5.6 months (HR 0.57)

• Median OS: 23.7 vs 18.7 months (HR 0.79)

• ORR: 63% vs 29%

• Median duration of response: 12.3 vs 7.1 months

• Grade ≥3 treatment-related adverse events were comparable between groups, with low discontinuation rates and no treatment-related deaths.

Take-home message: Dato-DXd demonstrated clinically meaningful improvements in both progression-free and overall survival, supporting its role as a first-line treatment option for patients with advanced TNBC who are not candidates for immunotherapy.

#BreastCancer #TNBC #MedicalOncology #ASCO #ESMO #AntibodyDrugConjugates #DatoDXd #MVOnco

[Benlazar S M A @smbenlazar]

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant https://t.co/LS0V44lDzN

[MV Chandrakanth @ChandrakanthMv]

DENOSUMAB DE-ESCALATION

For years, monthly denosumab has been the standard for patients with bone metastases.

But after initial therapy, do patients really need treatment every 4 weeks indefinitely?

REDUSE 96/12 addressed this question in 1,380 patients with breast cancer or mCRPC and bone metastases.

After 4 initial monthly doses:

• Every 12-week dosing achieved non-inferior skeletal protection • Time to first symptomatic skeletal event: 56.6 vs 56.5 months HR 1.02

Importantly:

• Hypocalcemia decreased from 46% → 30% • Osteonecrosis of the jaw decreased from 8.5% → 6.9%

The message is simple:

Less frequent treatment may preserve efficacy while reducing toxicity and treatment burden.

A potentially practice-changing maintenance strategy for bone metastases.

#MVOnco #ASCO2026 #Denosumab #BoneMetastases #BreastCancer #mCRPC #SupportiveCare #BoneHealth #Oncology #MedTwitter #OncTwitter

[Abdul Muqtadir Abbasi @AbbasiMuqtadir]

🧵 How to Read Flow Cytometry in Acute Leukemia (Step-by-Step)
1️⃣ Start with the CD45 vs Side Scatter (SSC) plot

This is your map.

Key points
Blasts → CD45 dim / low SSC
Lymphocytes → CD45 bright / low SSC
Granulocytes → CD45 moderate / high SSC
📌 Rule:
If you can’t clearly identify the blast gate, stop. Re-gate first

#MedTwitter,#MedEd , #Hematology, #HemeTwitter, #MedStudent

[Muzaffar Qazilbash @Transplant_Doc]

Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens using carfilzomib #mmsm #bmtsm @BloodPortfolio https://t.co/7Ky0GVEuum

[Benlazar S M A @smbenlazar]

How I individualize frontline treatment for chronic-phase CML https://t.co/kxbezet7nH #leusm

[Benlazar S M A @smbenlazar]

How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to Know https://t.co/PH1XNpp7S2 #mdpijcm via @JCM_MDPI #leusm

[Thanos Dimopoulos @thanosdimop]

Just published! Updated EHA-EMN guidelines for the diagnosis, treatment and follow-up of #MultipleMyeloma! #mmsm https://t.co/Xfg7vrAcTH
@EHA_Hematology @EMN_EuMMnet @UoATherapeutics

[OncoAlert @OncoAlert]

News From Industry
Source: AstraZeneca

The European Commission has approved AstraZeneca’s Imfinzi (durvalumab) as the first and only perioperative immunotherapy for resectable muscle-invasive #BladderCancer (MIBC), based on results from the Phase III NIAGARA trial. In combination with gemcitabine and cisplatin as neoadjuvant therapy followed by Imfinzi monotherapy after surgery, the regimen demonstrated a 32% reduction in the risk of recurrence, progression, or death, and a 25% reduction in mortality compared to neoadjuvant chemotherapy with surgery alone.

At two years, 67.8% of patients receiving the Imfinzi-based regimen were event-free and 82.2% were alive, highlighting its significant benefit in improving both event-free and overall survival.

https://t.co/S9m7uPA7R9

OncoAlert GU Faculty
@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen
@EfstathiouEleni @tompowles1 @BraunMDPhD @cdanicas
@DrYukselUrun

#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua

[Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD]

🚨 Tocilizumab Prophylaxis for Patients with Multiple Myeloma Treated with Bispecific Antibodies
Critical to Move all Future BiTEs to outpatient especially in community clinics

🧵1/Can we prevent CRS in myeloma patients receiving bispecific antibodies?
New real-world data from @SylvesterCancer suggests yes — with prophylactic tocilizumab.
Let’s break down the findings in @BloodAdvJournal. 👇
#mmsm #MedEd #MedTwitter #USMIRC @OncoAlert @USMIRCNEWS #myeloma #سرطان_الدم #المايلوما

[Bread & Butter Haematology @MorphologyAmigo]

Recently had a Young APL
I figured a "Morphological Refresher" would serve the greater good
Just Remember
🚨Act Early / Treat Coagulopathy / Start ATRA
🚨If an APL starts Bleeding the boat has most likely sailed⛵️
#hematology #medtwitter #meded #Medicine

[Vivek Subbiah, MD @VivekSubbiah]

🚨 Wow! #ASCO25 @ASCO was absolutely massive!
10 @NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert

[JAMA Oncology @JAMAOnc]

Viewpoint: The rise of social media and #AI in oncology has transformed scientific communication but also fuels bias, misinterpretation, and financial conflicts of interest.

https://t.co/gjsg9IpRwU @oncoblogger

[Oncology Brothers @OncBrothers]

This is amazing and will likely become the new SoC… but… how I wish there was that third arm to tell us how much benefit there is from postOP IO (same struggle in TNBC (KN522👇), NSCLC (AEGEAN 👇), soon in bladder cancer (NIAGARA 👇) and now MATTERHORN! #OncTwitter

[Siba El Hussein, MD @SibaElHussein]

https://t.co/TWAPCQaZds

[Oncology Brothers @OncBrothers]

2024 approvals: Summary of 6 new drugs/indications in GI Malignancies by @US_FDA

1. #LiposomalIrinotecan
2. #Adagrasib
3. #Zolbetuximab
4. #Zanidatamab
5. #Zenocutuzumab
6. #Encorafenib

#gism #OncTwitter #MedTwitter #PancChat